# $[^{125}I]$ - $[NLE^4, D-PHE^7]$ - $\alpha$ -MELANOCYTE STIMULATING HORMONE

Product Number: NEX352

## [<sup>125</sup>I]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]-α-MSH

Ac-Ser-[<sup>125</sup>I]Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH<sub>2</sub>

### LOT SPECIFIC INFORMATION

CALCULATED AS OF:	20-Jan-2025			
LOT NUMBER:	IM22150			
SPECIFIC ACTIVITY:		TBq/mmol Ci/mmol MBq/μg μCi/μg		
CONCENTRATION:	3.0 82.1	1		
RADIOCHEMICAL PURITY:		≥ 95%		

Package Size Information					
Volume					
0.20 mL					
1.00 mL					

MOLECULAR WEIGHT: ~1770

**PACKAGING**: [<sup>125</sup>I]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]-α -MSH is in a solution containing 0.08M Tris HCl, 0.08M NaCl, 0.05M β-mercaptoethanol, 0.25% BSA, 50 KIU/ml Trasylol<sup>®</sup>, (pH 8.5): ethanol, 5:1. It is shipped on dry ice.

**STABILITY AND STORAGE:** [<sup>125</sup>I]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH should be stored at -20°C. Under these conditions the product is stable and usable for at least six weeks after fresh lot date.

**SPECIFIC ACTIVITY:** The initial specific activity of [ $^{125}I$ ]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH is 2200 Ci/mmol, (81 TBq/mmol), 1243 µCi/µg (46 MBq/ [g). Preparative HPLC is used to separate unlabeled [NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH from [ $^{125}I$ ]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH. Upon decay, [ $^{125}I$ ]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on  $^{125}I$  decay and decay catastrophe of  $^{125}I$  labeled compounds are available.<sup>1-5</sup>

**RADIOCHEMICAL PURITY:** Initially greater than 95% radiochemically pure as determined by HPLC.

**PREPARATIVE PROCEDURE:** [NIe<sup>4</sup>, D-Phe<sup>7</sup>]-α-MSH is radioiodinated with no carrier added <sup>125</sup>I using a modification of the Hunter and Greenwood method<sup>6</sup> and purified by reversed phase HPLC.

**AVAILABILITY:** [ $^{125}$ I]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH is routinely available from stock and prepared fresh and packaged for shipment on the third Monday of each month. Please inquire for larger package sizes.

**APPLICATIONS:** [<sup>125</sup>I]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH is a highly potent and metabolically stable analog of  $\alpha$ -MSH.<sup>7</sup> [<sup>125</sup>I]-[NIe<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH can be used to label all subtypes of melanocortin receptors with high affinity and low non-specific binding.

**HAZARD WARNING:** This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes. It is toxic and flammable. Target organs are the central nervous system, respiratory system, kidneys and liver.

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface.

#### **REFERENCES:**

- 1. Doyle, V.M., Buhler, F.R., Burgisser, E., Eur. J. Pharm. <u>99</u> 353 (1984).
- 2. Schmidt, J., *J. Biol. Chem* . <u>259</u> 1660 (1984).
- 3. Loring (1982).
- 4. Berridge, M.S., Jiang, V.W., Welch, M.J., Rad. Res. <u>82</u> 467 (1980).
- 5. Charlton, D.E., *Rad. Res*. <u>107</u> 163 (1986).
- 6. Hunter and Greenwood, F.C., Nature 194 495 (1962).
- 7. Hruby, V.J., Lu, D., Sharma, S.D., de L. Castrucci, A., Kesterson, R.A., Al-Obeidi, F.A., Hadley, M.E., Cone, R.D.,
  - J. Med. Chem. 38 3451-61 (1995).

#### IODINE-125 DECAY CHART HALF LIFE=60 days

#### Radiations Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	0.977	0.955	0.933	0.912	0.891	0.871	0.851	0.831	0.812
20	0.794	0.776	0.758	0.741	0.724	0.707	0.691	0.675	0.660	0.645
40	0.630	0.616	0.602	0.588	0.574	0.561	0.548	0.536	0.524	0.512
60	0.500	0.489	0.477	0.467	0.456	0.445	0.435	0.425	0.416	0.406
80	0.397	0.388	0.379	0.370	0.362	0.354	0.345	0.338	0.330	0.322
100	0.315	0.308	0.301	0.294	0.287	0.281	0.274	0.268	0.262	0.256
120	0.250	0.244	0.239	0.233	0.228	0.223	0.218	0.213	0.208	0.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA

(800) 762-4000 www.revvity.com For a complete listing of our global offices, visit <u>www.revvity.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.